Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avacta Group plc ( (GB:AVCT) ) has provided an announcement.
Avacta Group PLC announced an upcoming presentation of their pre|CISION® dual payload peptide drug conjugate delivery system data, following their participation in the 2025 AACR-NCI-EORTC International Molecular Targets Congress. The presentation, scheduled for October 29, 2025, will be accessible to existing and potential shareholders, allowing them to engage with the company’s leadership and submit questions, potentially impacting Avacta’s market engagement and stakeholder relations.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £63.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Spark’s Take on GB:AVCT Stock
According to Spark, TipRanks’ AI Analyst, GB:AVCT is a Neutral.
Avacta Group plc’s stock score is primarily impacted by its challenging financial performance, characterized by negative profitability and high leverage. While there is some positive momentum in technical indicators and progress in clinical programs, financial constraints and valuation concerns weigh heavily on the overall score.
To see Spark’s full report on GB:AVCT stock, click here.
More about Avacta Group plc
Avacta is a clinical stage life sciences company focused on developing an innovative drug delivery platform called pre|CISION®. This platform aims to repurpose oncology drugs as peptide drug conjugate (PDC) payloads, reducing toxicity and side effects by concentrating the drug directly in tumors.
Average Trading Volume: 2,931,299
Technical Sentiment Signal: Hold
Current Market Cap: £259.1M
See more insights into AVCT stock on TipRanks’ Stock Analysis page.